TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

Molecular Therapy Oncolytics

Volumn 7, Issue , 2017, Pages 17-26

  Hutzen, Brian ^a   Chen, Chun Yu ^a   Wang, Pin Yi ^a   Sprague, Les ^b   Swain, Hayley M ^a   Love, Julia ^a   Conner, Joe ^c   Boon, Louis ^d   Cripe, Timothy P ^a,e  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c SORRENTO THERAPEUTICS   (United States)

^d BIOCEROS   (Netherlands)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

childhood sarcoma; herpes virus; immunotherapy; oncolytic virotherapy; oncolytic virus; rhabdomyosarcoma; smad signaling; T cell; TGF

Indexed keywords

A 8301; HSV 1716; PROTEIN INHIBITOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL LINE; SURVIVAL TIME; TGF BETA SIGNALING; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; VIRUS REPLICATION;

EID: 85041132284     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1016/j.omto.2017.09.001     Document Type: Article

References (37)

1. Smith, M.A., Altekruse, S.F., Adamson, P.C., Reaman, G.H., Seibel, N.L., Declining childhood and adolescent cancer mortality. Cancer 120 (2014), 2497–2506.
2. Leddon, J.L., Chen, C.Y., Currier, M.A., Wang, P.Y., Jung, F.A., Denton, N.L., Cripe, K.M., Haworth, K.B., Arnold, M.A., Gross, A.C., et al. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol Ther Oncolytics, 1, 2015, 14010.
3. Currier, M.A., Adams, L.C., Mahller, Y.Y., Cripe, T.P., Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther. 12 (2005), 407–416.
4. Eshun, F.K., Currier, M.A., Gillespie, R.A., Fitzpatrick, J.L., Baird, W.H., Cripe, T.P., VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Ther. 17 (2010), 922–929.
5. Currier, M.A., Gillespie, R.A., Sawtell, N.M., Mahller, Y.Y., Stroup, G., Collins, M.H., Kambara, H., Chiocca, E.A., Cripe, T.P., Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol. Ther. 16 (2008), 879–885.
6. Chen, C.Y., Wang, P.Y., Hutzen, B., Sprague, L., Swain, H.M., Love, J.K., Stanek, J.R., Boon, L., Conner, J., Cripe, T.P., Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models. Sci. Rep., 7, 2017, 2396.
7. Saha, D., Wakimoto, H., Rabkin, S.D., Oncolytic herpes simplex virus interactions with the host immune system. Curr. Opin. Virol. 21 (2016), 26–34.
8. Keller, B.A., Bell, J.C., Oncolytic viruses-immunotherapeutics on the rise. J. Mol. Med. (Berl.) 94 (2016), 979–991.
9. Andtbacka, R.H., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K.A., Amatruda, T., Zager, J.S., Cranmer, L., Hsueh, E., et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann. Surg. Oncol. 23 (2016), 4169–4177.
10. Andtbacka, R.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K.A., Spitler, L.E., Puzanov, I., Agarwala, S.S., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33 (2015), 2780–2788.
11. Rajani, K.R., Vile, R.G., Harnessing the power of onco-immunotherapy with checkpoint inhibitors. Viruses 7 (2015), 5889–5901.
12. Woller, N., Gürlevik, E., Fleischmann-Mundt, B., Schumacher, A., Knocke, S., Kloos, A.M., Saborowski, M., Geffers, R., Manns, M.P., Wirth, T.C., et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol. Ther. 23 (2015), 1630–1640.
13. Cassady, K.A., Haworth, K.B., Jackson, J., Markert, J.M., Cripe, T.P., To Infection and beyond: the multi-pronged anti-cancer mechanisms of oncolytic viruses. Viruses, 8, 2016, 8.
14. Puzanov, I., Milhem, M.M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K.S., Anderson, A., Chou, J., et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34 (2016), 2619–2626.
15. Akhurst, R.J., Hata, A., Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11 (2012), 790–811.
16. Yoshimura, A., Muto, G., TGF-β function in immune suppression. Curr. Top. Microbiol. Immunol. 350 (2011), 127–147.
17. Pickup, M., Novitskiy, S., Moses, H.L., The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer 13 (2013), 788–799.
18. Padua, D., Massagué J., Roles of TGFbeta in metastasis. Cell Res. 19 (2009), 89–102.
19. Bouché M., Canipari, R., Melchionna, R., Willems, D., Senni, M.I., Molinaro, M., TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells. FASEB J. 14 (2000), 1147–1158.
20. Wang, S., Guo, L., Dong, L., Guo, L., Li, S., Zhang, J., Sun, M., TGF-beta1 signal pathway may contribute to rhabdomyosarcoma development by inhibiting differentiation. Cancer Sci. 101 (2010), 1108–1116.
21. Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., de Gramont, A., Targeting the TGFβ pathway for cancer therapy. Pharmacol. Ther. 147 (2015), 22–31.
22. Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K., Node, M., Imamura, T., The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 96 (2005), 791–800.
23. MacKie, R.M., Stewart, B., Brown, S.M., Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357 (2001), 525–526.
24. Cripe, T. (2009). HSV1716 in patients with non-central nervous system (non-CNS) solid tumors. Report of the U.S. National Institutes of Health. May 2009, NCT00931931. http://clinicaltrials.gov/show/NCT00931931.
25. Streby, K.A., Geller, J.I., Currier, M.A., Warren, P.S., Racadio, J.M., Towbin, A.J., Vaughan, M.R., Triplet, M., Ott-Napier, K., Dishman, D.J., et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin. Cancer Res. 23 (2017), 3566–3574.
26. Benencia, F., Courrèges, M.C., Conejo-García, J.R., Mohamed-Hadley, A., Zhang, L., Buckanovich, R.J., Carroll, R., Fraser, N., Coukos, G., HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol. Ther. 12 (2005), 789–802.
27. Benencia, F., Courrèges, M.C., Fraser, N.W., Coukos, G., Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol. Ther. 7 (2008), 1194–1205.
28. Meadors, J.L., Cui, Y., Chen, Q.R., Song, Y.K., Khan, J., Merlino, G., Tsokos, M., Orentas, R.J., Mackall, C.L., Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatr. Blood Cancer 57 (2011), 921–929.
29. Mandl, S.J., Rountree, R.B., Dalpozzo, K., Do, L., Lombardo, J.R., Schoonmaker, P.L., Dirmeier, U., Steigerwald, R., Giffon, T., Laus, R., Delcayre, A., Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunol. Immunother. 61 (2012), 19–29.
30. Han, J., Chen, X., Chu, J., Xu, B., Meisen, W.H., Chen, L., Zhang, L., Zhang, J., He, X., Wang, Q.E., et al. TGFβ treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer Res. 75 (2015), 5273–5282.
31. Ilkow, C.S., Marguerie, M., Batenchuk, C., Mayer, J., Ben Neriah, D., Cousineau, S., Falls, T., Jennings, V.A., Boileau, M., Bellamy, D., et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat. Med. 21 (2015), 530–536.
32. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., Fujita, T., The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5 (2004), 730–737.
33. Hu, Z., Zhang, Z., Guise, T., Seth, P., Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum. Gene Ther. 21 (2010), 1623–1629.
34. Hu, Z., Gupta, J., Zhang, Z., Gerseny, H., Berg, A., Chen, Y.J., Zhang, Z., Du, H., Brendler, C.B., Xiao, X., et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum. Gene Ther. 23 (2012), 871–882.
35. Zhang, Z., Hu, Z., Gupta, J., Krimmel, J.D., Gerseny, H.M., Berg, A.F., Robbins, J.S., Du, H., Prabhakar, B., Seth, P., Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther. 19 (2012), 630–636.
36. Thomas, D.A., Massagué J., TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8 (2005), 369–380.
37. Wan, Y.Y., Flavell, R.A., ‘Yin-Yang’ functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol. Rev. 220 (2007), 199–213.